IL140917A0 - Human anti-factor ix/ixa antibodies - Google Patents

Human anti-factor ix/ixa antibodies

Info

Publication number
IL140917A0
IL140917A0 IL14091799A IL14091799A IL140917A0 IL 140917 A0 IL140917 A0 IL 140917A0 IL 14091799 A IL14091799 A IL 14091799A IL 14091799 A IL14091799 A IL 14091799A IL 140917 A0 IL140917 A0 IL 140917A0
Authority
IL
Israel
Prior art keywords
factor
ixa
fix
human anti
inhibiting
Prior art date
Application number
IL14091799A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL140917A0 publication Critical patent/IL140917A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL14091799A 1998-08-28 1999-08-26 Human anti-factor ix/ixa antibodies IL140917A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03
PCT/US1999/019453 WO2000012562A1 (en) 1998-08-28 1999-08-26 HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (1)

Publication Number Publication Date
IL140917A0 true IL140917A0 (en) 2002-02-10

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14091799A IL140917A0 (en) 1998-08-28 1999-08-26 Human anti-factor ix/ixa antibodies

Country Status (15)

Country Link
US (3) US6624295B1 (de)
EP (1) EP1107996B1 (de)
JP (1) JP4638035B2 (de)
CN (1) CN1183160C (de)
AT (1) ATE217889T1 (de)
AU (1) AU766551C (de)
BR (1) BR9913435A (de)
CA (1) CA2341276C (de)
DE (1) DE69901569T2 (de)
DK (1) DK1107996T3 (de)
ES (1) ES2177316T3 (de)
IL (1) IL140917A0 (de)
NZ (1) NZ509430A (de)
PT (1) PT1107996E (de)
WO (1) WO2000012562A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
NZ522632A (en) * 2000-05-15 2005-05-27 Smithkline Beecham Corp Antithrombotic agents
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) * 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
DK1905839T4 (da) * 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
CA2793143C (en) 2010-03-30 2020-04-28 Gustav Gilljam Process for the purification of a growth factor protein
ES2740825T3 (es) * 2010-03-30 2020-02-06 Octapharma Ag Un procedimiento de purificación de proteínas dependientes de vitamina K
KR101747991B1 (ko) * 2010-04-13 2017-06-19 메디뮨 엘엘씨 Ｔｒａｉｌ ｒ2 특이적 다량체 스캐폴드
CA2834432C (en) * 2011-05-23 2020-01-07 Sekisui Medical Co., Ltd. Method of inhibiting nonspecific reaction in pivka-ii assay reagent
US9623118B2 (en) * 2015-09-01 2017-04-18 Immunwork Inc. Multi-arm linker constructs for treating pathological blood clots
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
WO1991016353A1 (en) 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
RU2170257C2 (ru) 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
DE69901569D1 (de) 2002-06-27
WO2000012562A1 (en) 2000-03-09
US20060088534A1 (en) 2006-04-27
DE69901569T2 (de) 2002-12-19
ATE217889T1 (de) 2002-06-15
AU766551C (en) 2005-02-17
US7354585B2 (en) 2008-04-08
CA2341276C (en) 2005-10-11
DK1107996T3 (da) 2002-09-16
JP2002523081A (ja) 2002-07-30
EP1107996A1 (de) 2001-06-20
ES2177316T3 (es) 2002-12-01
CN1317015A (zh) 2001-10-10
AU766551B2 (en) 2003-10-16
CA2341276A1 (en) 2000-03-09
US6624295B1 (en) 2003-09-23
US20060193851A1 (en) 2006-08-31
PT1107996E (pt) 2002-10-31
US7049411B2 (en) 2006-05-23
CN1183160C (zh) 2005-01-05
JP4638035B2 (ja) 2011-02-23
EP1107996B1 (de) 2002-05-22
NZ509430A (en) 2002-04-26
AU5692399A (en) 2000-03-21
BR9913435A (pt) 2001-09-25

Similar Documents

Publication Publication Date Title
IL140917A0 (en) Human anti-factor ix/ixa antibodies
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1095357A1 (en) Factor vii or viia gla domain variants
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
MEP8209A (en) Modified factor viii
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
IL129592A0 (en) 5-HT1f agonists
HK1071521A1 (en) Use of a composition comprising cis-clomiphene andtrans-clomiphene in the preparation of a medicament for increasing serum levels of testosterone
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
HU9700903D0 (en) Sulfonamide-substituted chromanes, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
YU13301A (sh) Muskarinski agonisti i antagonisti
GB0216001D0 (en) Process and composition
SE9802937D0 (sv) Novel compounds
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired